ADCT vs PSA · rev $70.8M vs rev $4.82B
ADC Therapeutics SA (ADCT) versus PSA (PSA) — a side-by-side from cached financials, not a winner call.
ADC Therapeutics SA (ADCT) is a biotechnology company listed on NYSE.
PSA (PSA) common stock.
Latest reported ADCT revenue for 2024-12-31 was $70.8M. Net income was -$157.8M. Revenue was up 1.8% from 2023-12-31 to 2024-12-31. ADCT currently screens at market cap $141.2M.
Latest reported PSA revenue for 2025-12-31 was $4.82B. Net income was $1.78B. Revenue was up 2.7% from 2024-12-31 to 2025-12-31. PSA currently screens at market cap $0.
ADCT currently screens at market cap $141.2M. PSA currently screens at market cap $0.
Not investment advice. Open the ADCT and PSA stock pages for the full models.
Not investment advice.